Selected article for: "candidate vaccine and challenge model"
Author: Shehata, Mahmoud M.; Kandeil, Ahmed; Mostafa, Ahmed; Mahmoud, Sara H.; Gomaa, Mokhtar R.; El-Shesheny, Rabeh; Webby, Richard; Kayali, Ghazi; A. Ali, Mohamed
Title: A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice
  • Document date: 2019_12_2
    • ID: 15q6qr4z_19
    Snippet: In summary, we demonstrated a new platform for generating replication-competent recombinant influenza chimeric bivalent 5 + 3 virus containing an immunogenic short peptide of MERS-CoV in the NA gene using reverse genetics technology. The rescued chimeric bivalent influenza virus could replicate well and was propagated for multiple passages in embryonated eggs. The novel recombinant bivalent IAV provided nAbs against MERS-CoV and HAI antibodies ag.....
    Document: In summary, we demonstrated a new platform for generating replication-competent recombinant influenza chimeric bivalent 5 + 3 virus containing an immunogenic short peptide of MERS-CoV in the NA gene using reverse genetics technology. The rescued chimeric bivalent influenza virus could replicate well and was propagated for multiple passages in embryonated eggs. The novel recombinant bivalent IAV provided nAbs against MERS-CoV and HAI antibodies against H1N1pdm09 influenza viruses in vaccinated mice. Future studies for evaluation of this candidate vaccine for protective capacity in a murine-challenge model and non-human primates as a first step before human trails to generate a safe and well replicating candidate strain for human vaccines are recommended.

    Search related documents:
    Co phrase search for related documents
    • bivalent influenza virus and immunogenic MERS CoV short peptide: 1
    • bivalent influenza virus and influenza virus: 1, 2
    • bivalent influenza virus and MERS CoV short peptide: 1
    • bivalent influenza virus and NA gene: 1
    • candidate vaccine and future study: 1, 2, 3
    • candidate vaccine and HAI antibody: 1
    • candidate vaccine and human vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • candidate vaccine and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • candidate vaccine and murine challenge: 1
    • candidate vaccine and murine challenge model: 1
    • candidate vaccine evaluation and human vaccine: 1, 2, 3
    • candidate vaccine evaluation and influenza virus: 1
    • chimeric bivalent influenza virus and influenza virus: 1
    • future study and human vaccine: 1
    • future study and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • genetic technology and influenza virus: 1
    • HAI antibody and influenza virus: 1, 2, 3, 4, 5, 6, 7
    • human vaccine and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • human vaccine and multiple passage: 1